Pfizer Company Profile (NYSE:PFE)

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:PFE
  • CUSIP: 71708110
  • Web:
  • Market Cap: $201.53409 billion
  • Outstanding Shares: 5,967,844,000
Average Prices:
  • 50 Day Moving Avg: $32.70
  • 200 Day Moving Avg: $33.07
  • 52 Week Range: $29.83 - $37.39
  • Trailing P/E Ratio: 28.41
  • Foreward P/E Ratio: 12.32
  • P/E Growth: 2.35
Sales & Book Value:
  • Annual Revenue: $52.6 billion
  • Price / Sales: 3.83
  • Book Value: $9.79 per share
  • Price / Book: 3.45
  • Annual Dividend: $1.28
  • Dividend Yield: 3.8%
  • EBIDTA: $19.51 billion
  • Net Margins: 13.76%
  • Return on Equity: 23.68%
  • Return on Assets: 8.48%
  • Debt-to-Equity Ratio: 0.52%
  • Current Ratio: 1.25%
  • Quick Ratio: 1.03%
  • Average Volume: 21.73 million shs.
  • Beta: 1.02
  • Short Ratio: 1.89

Frequently Asked Questions for Pfizer (NYSE:PFE)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Thursday, June 22nd. Shareholders of record on Friday, August 4th will be given a dividend of $0.32 per share on Friday, September 1st. This represents a $1.28 annualized dividend and a yield of 3.79%. The ex-dividend date of this dividend is Wednesday, August 2nd. View Pfizer's Dividend History.

How were Pfizer's earnings last quarter?

Pfizer, Inc. (NYSE:PFE) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.02. The firm had revenue of $12.78 billion for the quarter, compared to analysts' expectations of $13.09 billion. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. The company's revenue was down 1.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 EPS. View Pfizer's Earnings History.

When will Pfizer make its next earnings announcement?

Pfizer is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $2.50-2.60 for the period, compared to the Thomson Reuters consensus estimate of $2.55. The company issued revenue guidance of $52-54 billion, compared to the consensus revenue estimate of $53.15 billion.

Where is Pfizer's stock going? Where will Pfizer's stock price be in 2017?

18 analysts have issued 1-year price targets for Pfizer's stock. Their forecasts range from $31.00 to $53.00. On average, they expect Pfizer's share price to reach $37.63 in the next twelve months. View Analyst Ratings for Pfizer.

What are analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

  • 1. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
  • 2. According to Zacks Investment Research, "Pfizer has been working on strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. While the Hospira acquisition significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal strengthened its cancer franchise by adding Xtandi to its portfolio. Pfizer’s new products like Ibrance should do well and drive revenues in 2017 while cost-savings and share buybacks should boost earnings. Pfizer’s shares surpassed that of large-cap pharma industry in the past one year. The company has a positive record of earnings surprises in recent quarters. Investor focus will remain on the stock as Pfizer has several key pipeline milestones in 2017. However, headwinds remain in the form of genericization, pricing pressure and rising competition, which will continue to hamper top-line growth. Estimates have declined slightly ahead of its Q4 earnings release." (1/25/2017)
  • 3. Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in June. As of June 15th, there was short interest totalling 44,380,006 shares, an increase of 2.9% from the May 31st total of 45,710,703 shares. Based on an average trading volume of 21,468,870 shares, the short-interest ratio is presently 2.1 days. Currently, 0.7% of the company's stock are sold short.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

  • Ian C. Read, Chairman of the Board, Chief Executive Officer
  • Frank A. D'Amelio, Chief Financial Officer, Executive Vice President - Business Operations
  • Albert Bourla, Group President - Pfizer Innovative Health
  • Mikael Dolsten M.D., Ph.D., President - Worldwide Research and Development
  • John D. Young, Group President - Pfizer Essential Health
  • Rady A. Johnson II, Executive Vice President, Chief Compliance and Risk Officer
  • Douglas M. Lankler, Executive Vice President, General Counsel
  • Charles H. Hill III, Executive Vice President - Worldwide Human Resources
  • Freda C. Lewis-Hall M.D., Executive Vice President, Chief Medical Officer
  • Kirsten Lund-Jurgensen, Executive Vice President, President - Pfizer Global Supply

Who owns Pfizer stock?

Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.50%), Vanguard Group Inc. (6.88%), State Street Corp (5.37%), Wellington Management Group LLP (1.23%), Bank of New York Mellon Corp (1.18%) and State Farm Mutual Automobile Insurance Co. (1.00%). Company insiders that own Pfizer stock include Albert Bourla, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson and Sally Susman. View Institutional Ownership Trends for Pfizer.

Who sold Pfizer stock? Who is selling Pfizer stock?

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., APG Asset Management N.V., Parametric Portfolio Associates LLC, Canada Pension Plan Investment Board, Lazard Asset Management LLC, Ameriprise Financial Inc., Caisse DE Depot ET Placement DU Quebec and PNC Financial Services Group Inc.. Company insiders that have sold Pfizer stock in the last year include Albert Bourla, Anthony J Maddaluna, Charles H Hill, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

Who bought Pfizer stock? Who is buying Pfizer stock?

Pfizer's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Massachusetts Financial Services Co. MA, Cibc World Markets Corp, Vanguard Group Inc., Swiss National Bank, Wellington Management Group LLP, Morgan Stanley and Geode Capital Management LLC. View Insider Buying and Selling for Pfizer.

How do I buy Pfizer stock?

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of Pfizer stock can currently be purchased for approximately $33.75.

MarketBeat Community Rating for Pfizer (NYSE PFE)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  764 (Vote Outperform)
Underperform Votes:  350 (Vote Underperform)
Total Votes:  1,114
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pfizer (NYSE:PFE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $37.63 (11.48% upside)

Analysts' Ratings History for Pfizer (NYSE:PFE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017Jefferies Group LLCReiterated RatingNeutral$34.00LowView Rating Details
6/12/2017Morgan StanleyReiterated RatingNeutral$38.00 -> $35.00LowView Rating Details
5/16/2017Citigroup Inc.DowngradeNeutral -> Sell$38.00 -> $31.00LowView Rating Details
5/3/2017Barclays PLCReiterated RatingBuy$38.00LowView Rating Details
5/3/2017Sanford C. BernsteinReiterated RatingBuy$37.00LowView Rating Details
4/27/2017BMO Capital MarketsReiterated RatingHold$33.00LowView Rating Details
3/23/2017Societe GeneraleReiterated RatingNeutral$36.00LowView Rating Details
3/13/2017Credit Suisse GroupSet Price TargetBuy$38.00LowView Rating Details
2/17/2017Berenberg BankSet Price TargetNeutral$39.00N/AView Rating Details
2/16/2017Deutsche Bank AGReiterated RatingBuy$40.00N/AView Rating Details
2/2/2017Morningstar, Inc.Reiterated RatingBuyN/AView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/AView Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral$36.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/7/2016Bank of America CorporationReiterated RatingBuy$40.00 -> $36.00N/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
8/3/2016J P Morgan Chase & CoSet Price TargetBuy$40.00N/AView Rating Details
5/4/2016Independent Research GmbHSet Price TargetNeutral$37.00N/AView Rating Details
5/2/2016Leerink SwannLower Price TargetMarket Perform$37.00 -> $34.70N/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
2/16/2016SunTrust Banks, Inc.Lower Price TargetNeutral$37.00 -> $33.00N/AView Rating Details
1/26/2016Nord/LBReiterated RatingBuyN/AView Rating Details
12/2/2015Cowen and CompanyReiterated RatingBuy$43.00N/AView Rating Details
11/24/2015Evercore ISIReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 6/29/2015 forward)


Earnings History for Pfizer (NYSE:PFE)
Earnings by Quarter for Pfizer (NYSE:PFE)
Earnings History by Quarter for Pfizer (NYSE PFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017$0.67$0.69$13.09 billion$12.78 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pfizer (NYSE:PFE)
2017 EPS Consensus Estimate: $2.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.67$0.67$0.67
Q2 20172$0.62$0.66$0.64
Q3 20172$0.63$0.64$0.64
Q4 20172$0.56$0.60$0.58
(Data provided by Zacks Investment Research)


Current Dividend Information for Pfizer (NYSE:PFE)
Next Dividend:9/1/2017
Annual Dividend:$1.28
Dividend Yield:3.79%
Dividend Growth:7.70% (3 Year Average)
Payout Ratio:108.48% (Trailing 12 Months of Earnings)
50.00% (Based on This Year's Estimates)
46.72% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Dividend History by Quarter for Pfizer (NYSE PFE)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Pfizer (NYSE:PFE)
Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 69.97%
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.00View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.00View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.70View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.00View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.50View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.00View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.00View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pfizer (NYSE:PFE)
Latest Headlines for Pfizer (NYSE:PFE)
DateHeadline logo[$$] Cancer Drug Startup Vivace Therapeutics Raises $40 Million - June 28 at 4:46 PM logoPfizer’s Segment Performance in 1Q17 - June 28 at 4:46 PM logoPfizer’s Profitability in 1Q17 - June 28 at 4:46 PM logoPfizer a Top 25 Dividend Giant With 3.77% Yield (PFE) - June 27 at 7:19 PM logoPfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri - June 27 at 7:19 PM logoShocker: Merck Cholesterol Drug Yields Benefit Where Rivals Failed - June 27 at 7:19 PM logoA Look at Pfizer’s Revenue for 1Q17 - June 27 at 7:19 PM logoPfizer: Negative Signs? - Seeking Alpha - June 27 at 7:16 AM logoBreakfast Technical Briefing on Drug Makers Stocks -- Pfizer, Merck, AbbVie, and Johnson & Johnson - June 26 at 8:18 AM logoTrader shares top health-care play - June 26 at 8:18 AM logo3 Stocks to Help You Build Retirement Wealth - June 25 at 7:01 AM logoVertex on the Street: Analysts’ Recommendations in June 2017 - June 24 at 5:56 AM logoGreenwich Capital Commercial Funding Corp., 2005-GG3 -- Moody's Affirms Four Classes of GCCFC 2005-GG3 - June 24 at 5:56 AM logoPfizer, Inc. (PFE) Receives Average Rating of "Hold" from Brokerages - June 24 at 12:50 AM logoPfizer, Inc. (PFE) Rating Increased to Sell at BidaskClub - June 23 at 7:04 PM logoUPDATE: Pfizer (PFE) gets CRL on Epoetin Alfa Biosimilar - June 23 at 9:00 AM logoPfizer Declares 32-Cent Third-Quarter 2017 Dividend - June 23 at 9:00 AM logoPfizer Inc. – Value Analysis (NYSE:PFE) : June 22, 2017 - June 23 at 9:00 AM logo15 Great Dividend Stocks to Own Should the Surging Stock Market Plunge This Summer - June 23 at 9:00 AM logoPfizer, Inc. (PFE) Plans $0.32 Quarterly Dividend - June 22 at 6:46 PM logoFDA rejects Pfizer's marketing application for Epogen biosimilar - June 22 at 5:09 PM logoPfizer To Lose Exclusivity Of Key Brands - Seeking Alpha - June 22 at 5:05 AM logoTakeover rumors de jour: Pfizer taking out Bristol-Myers, ACADIA Pharma - June 21 at 11:26 AM logoPfizer Firing on All Cylinders - TheStreet - - June 21 at 1:37 AM logoBetter Buy: Pfizer Inc. vs. AbbVie Inc. -- The Motley Fool - Motley Fool - June 21 at 1:37 AM logoPfizer Firing on All Cylinders - June 21 at 1:37 AM logoPfizer Target of Unusually High Options Trading (PFE) - June 20 at 12:58 PM logoPfizer Target of Unusually Large Options Trading (PFE) - June 20 at 12:58 PM logoPfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine - June 19 at 7:54 PM logoTop Stock Reports for Chevron, Pfizer & Boeing - June 19 at 7:54 PM logoPfizer (PFE) Commences Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine - - June 19 at 10:29 AM logoCould Legalized Marijuana Be Making Big Pharma Nervous? - June 18 at 2:55 PM logoPfizer, Inc. (PFE) Earns "Neutral" Rating from Jefferies Group LLC - June 17 at 11:08 AM logoPfizer Reports Overall Efficacy In Xeljanz Oral Safety Study - June 16 at 8:49 AM logoPfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress - June 16 at 8:49 AM logo5 best bets in biotech: Expert - June 16 at 8:49 AM logoPfizer denies over-charging for cancer drugs in South Africa - June 14 at 11:32 PM logoPfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients - June 14 at 11:31 PM logoBasilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel - June 14 at 1:50 PM logoPfizer And Lilly Gets FDA Fast Track Designation For Tanezumab - June 13 at 7:20 PM logoFormer Pfizer Scientist Is Resurrecting Projects To Solve The Multidrug Resistant Bacteria Problem - June 13 at 7:20 PM logoPfizer, Eli Lilly Granted Accelerated Review for Non-Opiod Pain Relief Drug - June 13 at 7:20 PM logoEli Lilly stock rises 1.5% after pain drug gets fast track designation from FDA - June 13 at 10:29 AM logoNearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey - June 13 at 10:29 AM logoMerck: A Speed Bump For Keytruda? - June 13 at 10:29 AM logoInteresting March 2018 Stock Options for PFE - June 12 at 6:50 PM logoThe Winners of Trump's Offshore Tax Plan - June 12 at 6:50 PM logoPfizer, Inc. (PFE) Given a $35.00 Price Target by Morgan Stanley Analysts - June 12 at 10:36 AM logoPfizer: Buy Shares On Price Weakness - June 11 at 7:28 PM logoPfizer and Astellas amend late-stage study supporting expanded use of Xtandi, top-line data expected this year - June 9 at 8:38 AM



Pfizer (PFE) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by Staff